News

Povetacicept may be superior to current MG treatments: Early study

The experimental treatment povetacicept (ALPN-303) may be more effective than current available treatments for myasthenia gravis (MG), according to preclinical data from Alpine Immune Sciences, which is developing the therapy. Specifically, povetacicept outperformed Vyvgart (efgartigimod) and off-label rituximab at reducing disease activity in a mouse model of the…

Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG

The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under the brand name Zilbrysq, for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR). With this approval, Zilbrysq has now become the…